OpenEvidence has considered raising $200 million at a $20 billion valuation but is unlikely to move forward with the round, The Information reported July 17.
A source involved in the discussions told the news outlet the deal would dilute shares held by founders and existing investors. That same source said OpenEvidence has held acquisition talks with a large technology company in the past several months.
The AI-powered clinical reference platform is now generating roughly $300 million in annualized revenue, or about $25 million a month — double what it was bringing in seven months earlier, when the company was in talks to raise at a $12 billion valuation, according to the July 17 story. OpenEvidence closed that $250 million series D round, led by Thrive Capital and DST Global, in January.
OpenEvidence, which trains its models on peer-reviewed medical literature rather than open internet data, says it is used by more than 860,000 licensed U.S. clinicians and is running at roughly breakeven on a cash-flow basis.
Founded in 2022, OpenEvidence has raised about $700 million over the past year and counts New York City-based Mount Sinai Health System, Los Angeles-based Cedars-Sinai and Sacramento, Calif.-based Sutter Health among the health systems that have integrated the tool into clinical workflows.
Editor’s note: Becker’s reached out to OpenEvidence for comment and will update the story if the company responds.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.